Donna Wilcock, Ph.D., of the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) was awarded a $1.7 million National Institutes of Health grant for her lab’s exploration of adverse effects of two new Alzheimer’s disease drugs — aducanumab and lecanemab — which have been shown to slow the progression of cognitive decline.
20240208171546.png&width=400&height=400)
Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic®) for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms (HN). These diseases include Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis. Cobimetinib is an oral inhibitor of MEK1 and MEK2, currently approved to treat melanoma.
Binghamton University Assistant Professor of Chemistry Jennifer Hirschi recently received a Maximizing Investigators’ Research Award for $1.93 million from the National Institute of General Medical Sciences to study the mechanisms involved in catalytic reactions.
A study of 50 adult patients with cystic fibrosis (CF) has found that challenged urine bicarbonate excretion may offer a new, simple, and safe quantification of cystic fibrosis transmembrane conductance regulator (CFTR) function and the extent of its pharmacologic improvement. The study is published in Annals of Internal Medicine.
An analysis of the CHANCE-2 trial has found that persons with normal renal function receive greater benefit from antiplatelet therapy with ticagrelor–aspirin versus clopidogrel–aspirin. The analysis is published in Annals of Internal Medicine.
A multinational cohort study of persons with atrial fibrillation (AF) found that compared with all direct oral anticoagulants (DOACs), apixaban was associated with lower rates of gastrointestinal (GI) bleeding but similar rates of ischemic stroke, intracranial hemorrhage (ICH), and all-cause mortality. The findings are published in Annals of Internal Medicine.
UC San Diego researchers and others report that more than one-third of the COVID-19 patients who did not receive any treatment experienced complete resolution of symptoms for at least two consecutive days, but then subsequently reported a return of symptoms.
A new study led by Duke Health found that advanced practice clinicians received more payments from drug companies, while physicians accepted more funds from medical device companies. The same proportion of each group accepted payments, but the physicians received a much greater sum.
To expand access to safe, high-quality anesthesia services to veterans, Rep. Lauren Underwood (IL-D) along with 12 Congressional colleagues requested that CRNAs be granted full practice authority permanently across VA facilities.
A drug approved to treat breast cancer patients with mutations in the BRCA1 or BRCA2 genes may also benefit people who have other genetic mutations.
A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers.
ScienceMedia has joined Biocom California at the Provider level of membership, connecting to more than 1,700 member companies and 500,000 employees across California and beyond.
Researchers say hydroquinine could be an effective weapon against a germ that can cause serious infections in humans, mostly hospital patients.
A University of Kentucky Markey Cancer Center researcher’s team developed new chemical compounds that show promise as a potential anticancer therapy to treat aggressive tumors. The study led by Samuel G. Awuah, Ph.D., was published in Chemical Communications with Adedamola Arojojoye, a graduate student in Awuah’s lab as the paper’s first author.
New research from Yale Cancer Center reveals for the first time ever a differential clinical response to pembrolizumab in Lynch-like (mutated) vs methylated microsatellite instability-high (MSI-H) uterine cancer patients, increasing our understanding about the proportion of patients that derive benefit from immune checkpoint blockade.
Donald E. Arnold, M.D., FASA, was today elected as first vice president of the American Society of Anesthesiologists (ASA), the nation’s largest organization of physician anesthesiologists. Dr. Arnold was elected by the House of Delegates at the ANESTHESIOLOGY® 2022 annual meeting and will serve for one year.
The American Society of Anesthesiologists (ASA) today presented James D. Grant, M.D., MBA, FASA, with its 2021 Distinguished Service Award in recognition of his highly distinguished career as a physician anesthesiologist, enduring contributions to ASA members and deep commitment to advocating for the specialty and protecting patient safety.
American Society of Anesthesiologists names Michael W. Champeau, M.D., FASA, new president
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
